Pyrazine Derivative ENaC Blockers for Mucosal Hydration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory, obstructive, or allergic diseases, particularly those affecting airways, lack effective compounds that can efficiently manage mucosal hydration and fluid regulation across epithelial membranes.
Innovation Solution
Development of specific organic compounds, such as those represented by Formula I, which act as epithelial sodium channel (ENaC) blockers, promoting fluid accumulation on the mucosal side of airway epithelium to enhance mucus clearance and prevent mucus accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for inflammatory and obstructive airways diseases, then general symptom management is achieved, but effective management of mucosal hydration and fluid regulation is lacking
Solution Approach 1:
The patent modifies molecular parameters by developing pyrazine derivative compounds with specific structural features (substituents at positions 3 and 6, various R groups) to optimize ENaC blocking activity. This involves changing chemical parameters such as molecular weight, lipophilicity, and functional groups to achieve reliable mucosal hydration management while maintaining adaptability for different airways diseases including cystic fibrosis, COPD, and asthma
2Productivity
If ENaC blocking compounds are developed to promote fluid accumulation on mucosal side, then mucus clearance is enhanced, but complexity of compound structure increases
Solution Approach 1:
The patent segments the ENaC blocker molecule into distinct functional modules: a pyrazine core structure (providing the essential blocking activity), and variable substituent groups (R1-R10) that can be independently optimized. This segmentation allows the core structure to maintain high mucus clearance efficiency while peripheral groups are adjusted to manage structural complexity and improve pharmacokinetic properties
Solution Approach 2:
The patent applies local quality by assigning specific functions to different parts of the molecule: the pyrazine core provides the essential ENaC blocking function for mucus clearance, while specific substituents (such as R6-R9 on the aromatic ring and R10 side chain) are optimized locally to enhance solubility, reduce metabolic instability, and improve overall drug-like properties without compromising the core clearance mechanism
3Reliability
If current treatments are used for airways diseases, then general therapeutic effects are achieved, but effective compounds for specific ENaC blockade are lacking
Solution Approach 1:
The patent creates a universal pyrazine derivative platform that can effectively block ENaC channels across multiple disease conditions (cystic fibrosis, COPD, asthma). The core pyrazine structure with positions 3 and 6 substituted provides a multi-functional scaffold that maintains reliable ENaC blockade effectiveness while allowing various R group combinations to be synthesized using similar chemical pathways, thereby improving ease of manufacture across the drug series
Data Source
AI summary
Compounds of Formula I:and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.